Expert Interview
A Second Look: Discussing the Approval of Insmed's Brinsupri in non cystic fibrosis bronchiectasis, as well as potential of Treprostinil Palmitil Inhalation Powder (TPIP) for the treatment of Pulmonary Arterial Hypertension (PAH)
Ticker(s): INSMInstitution: Trinity Health Michigan
- Board-certified in pulmonary and internal medicine, and board-eligible in critical care.
- Manages 15 PAH patients
- Clinical interests include interstitial lung disease, lung cancer screening, and cystic fibrosis. Has published several publications and presented at numerous pulmonary and critical care conferences.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
